RCA
EW icon

Runnymede Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Runnymede Capital Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$3.62K – 126
2025
Q1 		$3.62K Hold
50
– – ﹤0.01% 243
2024
Q4 		$3.7K Buy
+50
New +$3.5K ﹤0.01% 236

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Runnymede Capital Advisors's EW Position: Q2 2025 in Review

Runnymede Capital Advisors sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 50 shares — an estimated $3.62K sold.

Runnymede Capital Advisors first reported a position in EW in Q4 2024 and held it in 2 quarters. The position peaked at $3.7K in Q4 2024. 1,261 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Runnymede Capital Advisors reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
  • Runnymede Capital Advisors sold 50 Edwards Lifesciences shares in Q2 2025, an estimated $3.62K.
  • Runnymede Capital Advisors first reported a position in Edwards Lifesciences in Q4 2024 and held it in 2 quarters.
  • Runnymede Capital Advisors's Edwards Lifesciences position peaked at $3.7K in Q4 2024.
  • 1,261 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Runnymede Capital Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.